Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 3

Results For "EBITDA-margin"

160 News Found

Siemens acquires Dotmatics for $5.1 billion to strengthen Life Sciences portfolio
Digitisation | April 07, 2025

Siemens acquires Dotmatics for $5.1 billion to strengthen Life Sciences portfolio

Increases Siemens’ industrial software total addressable market by $11 billion; aligns with strategic goal to accelerate customer innovation across industries


Zydus to acquire majority stake in Amplitude Surgical, France
News | March 12, 2025

Zydus to acquire majority stake in Amplitude Surgical, France

Amplitude Surgical is a European MedTech leader in high-quality, lower-limb orthopaedic technologies


Glenmark Pharma reports Q3 FY25 PAT at Rs. 348 Cr
News | February 17, 2025

Glenmark Pharma reports Q3 FY25 PAT at Rs. 348 Cr

Glenmark’s consolidated revenue was at Rs. 3,387.6 crore as against Rs. 2,506.7 crore recording an increase of 35.1% YoY


Akums reports Q3 FY25 adjusted PAT at Rs. 66.3 Cr
News | February 07, 2025

Akums reports Q3 FY25 adjusted PAT at Rs. 66.3 Cr

Branded formulation business continues to perform well across domestic and export markets


Gland Pharma reports Q3 FY25 revenue at Rs. 1,384 Cr
News | February 04, 2025

Gland Pharma reports Q3 FY25 revenue at Rs. 1,384 Cr

Our Q3 FY25 revenue was at Rs. 1,384.1 crore with an EBITDA of Rs. 360 crore resulting in a 26% EBITDA margin


Nectar Lifesciences posts Q3 FY25 PAT at Rs. 7.84 Cr
News | February 03, 2025

Nectar Lifesciences posts Q3 FY25 PAT at Rs. 7.84 Cr

Revenue from Operations for Q3 FY25 was Rs. 454.33 crore,


Strides reports 14.6% growth in Q3 FY25 revenue
News | January 31, 2025

Strides reports 14.6% growth in Q3 FY25 revenue

EBITDA grew 46.9% YoY to Rs. 210.3 crore with EBITDA margin at 18.2%, grew 401 bps YoY and the reported PAT at Rs. 90 crore


Piramal Pharma Q3 FY25 revenue up 13%
News | January 30, 2025

Piramal Pharma Q3 FY25 revenue up 13%

CDMO business delivered high-teen revenue growth for 9MFY25 driven by continued traction in the on-patent commercial manufacturing and generic API business


Granules India Q3 FY25 PAT drops 6% to Rs 118 Cr
News | January 27, 2025

Granules India Q3 FY25 PAT drops 6% to Rs 118 Cr

The company said it voluntarily paused production at the Gagillapur plant in September 2024 for risk assessment on account of the USFDA observations


Mankind Pharma Q3 FY25 PAT dips 16% to Rs. 385 Cr
News | January 25, 2025

Mankind Pharma Q3 FY25 PAT dips 16% to Rs. 385 Cr

Q3 FY25 revenue up 24% to Rs 3,230 crore